Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Transplanted Brain Stem Cells Don't Trigger Rejection

By HospiMedica staff writers
Posted on 25 Jul 2003
Scientists have shown for the first time that brain stem cells are invisible to a transplant recipient's immune system and do not trigger the system to reject them, which may eliminate the need for tissue typing and immunosuppressive drugs. More...
The finding was published in the July 2003 issue of Stem Cells.

Certain sites in the body do not mount attacks against foreign tissue because it would be too self-destructive. These sites, known as "immune privileged,” include the brain, the eye, the digestive system, and the reproductive system. To test the suspicion that brain stem cells might be immune privileged, researchers took brain stem cells from mice in which the gene for green protein found in jellyfish had been inserted. These were placed in normal mice under the kidney capsule, the pouch in which the kidney is located, a site that always rejects transplanted tissue without close tissue typing or immunosuppressant drugs. After four weeks, the researchers examined the mice and found that the stem cells had not been rejected in any of the mice and had grown into normal tissue. They concluded that these neural stem cells must be invisible to the immune system.

To determine if the cells possessed the antigens most other tissues have, the researchers took other brain cells that were not stem cells from the green mice and implanted them in the normal mice. These cells were rejected, and when brain stem cells were then implanted in the normal mice, they were also rejected. This showed that brains stem cells do possess antigens but unless the recipient is primed or pre-immunized, the antigens are not visible to the immune system and not rejected.

"These findings are very exciting,” said lead author Michael Young, Ph.D., an assistant professor at Harvard Medical School (Boston, MA, USA). "Though we suspected brain stem cells might be protected in this way, this is the first documented evidence.”




Related Links:
Harvard Med. School

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.